DM
AKTX

Deerfield Management’s Akari Therapeutics AKTX Stock Holding History

Deerfield Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-312
Closed -$1.08M – 119
2017
Q4 		$1.08M Sell
312
-230
-42% -$887K 0.04% 96
2017
Q3 		$2.66M Sell
542
-481
-47% -$1.8M 0.12% 86
2017
Q2 		$3.77M Sell
1,023
-415
-29% -$3.28M 0.2% 72
2017
Q1 		$12.7M Hold
1,438
– – 0.49% 60
2016
Q4 		$8.1M Hold
1,438
– – 0.33% 64
2016
Q3 		$9.79M Hold
1,438
– – 0.46% 46
2016
Q2 		$15.5M Hold
1,438
– – 0.61% 51
2016
Q1 		$16.1M Hold
1,438
– – 0.69% 46
2015
Q4 		$16.7M Hold
1,438
– – 0.68% 53
2015
Q3 		$27.6M Buy
+1,438
New +$17M 1.07% 36

Other funds holding AKTX

HP
Hikari Power Tokyo, Japan $855M AUM 14.24% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Deerfield Management's AKTX Position: Q1 2018 in Review

Deerfield Management sold out of Akari Therapeutics (AKTX) in Q1 2018, closing a stake of 312 shares — an estimated $1.08M sold.

Deerfield Management first reported a position in AKTX in Q3 2015 and held it in 10 quarters. The position peaked at $27.6M in Q3 2015. 9 funds tracked by Wall St. Rank hold AKTX as of Q1 2018.

  • Deerfield Management reported no remaining Akari Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Deerfield Management sold 312 Akari Therapeutics shares in Q1 2018, an estimated $1.08M.
  • Deerfield Management first reported a position in Akari Therapeutics in Q3 2015 and held it in 10 quarters.
  • Deerfield Management's Akari Therapeutics position peaked at $27.6M in Q3 2015.
  • 9 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2018.

Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.